1 reports of this reaction
2.4% of all ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY reports
#10 most reported adverse reaction
BREAST CANCER is the #10 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, manufactured by Bath and Body Works, Distr.. There are 1 FDA adverse event reports linking ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY to BREAST CANCER. This represents approximately 2.4% of all 42 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY who experience breast cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER is a less commonly reported adverse event for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, but still significant enough to appear in the safety profile.
In addition to breast cancer, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY:
The following drugs have also been linked to breast cancer in FDA adverse event reports:
BREAST CANCER has been reported as an adverse event in 1 FDA reports for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER accounts for approximately 2.4% of all adverse event reports for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, making it a notable side effect.
If you experience breast cancer while taking ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.